The biopharmaceutical industry is going through a silent but profound transformation. While headlines tend to focus on blockbuster drugs or billion-dollar mergers, another movement is gathering momentum beneath the surface—one powered not by laboratory throughput alone, but by algorithmic intelligence. Antibody engineering, once defined by trial-and-error approaches and lengthy...